Bladder cancer laboratory findings

Jump to navigation Jump to search

Bladder cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Bladder cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Electrocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Biopsy

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bladder cancer laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bladder cancer laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bladder cancer laboratory findings

CDC on Bladder cancer laboratory findings

Bladder cancer laboratory findings in the news

Blogs on Bladder cancer laboratory findings

Directions to Hospitals Treating Bladder cancer

Risk calculators and risk factors for Bladder cancer laboratory findings

Steven C. Campbell, M.D., Ph.D.

Overview

Laboratory findings consistent with the diagnosis of bladder cancer include blood in the urine, Presence of abnormal cells in the urine, and elevated tumor markers.

Laboratory Findings

  • Blood in the urine
  • Urine cytology
  • Presence of abnormal cells
  • Bladder tumour–associated antigen (BTA)
  • Nuclear matrix proteins (NMP)
  • Mucin and carcinoembryonic antigen (CEA)
  • Complete blood count

References

  1. Bladder Cancer. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/bladder/diagnosis/?region=ab#urinetest Accessed on October, 6 2015

Template:WH Template:WS